AI-Waves-Nano Platform for Bio-Defense from unknown pathogens

特許 係属中 The patent applications are held in the sole and exclusive ownership of the inventor and have not been assigned, licensed, transferred, or contributed to any startup, company, or third party. Two related pending Italian patent applications (EPO report positive on first patent, about second patent following) describing an AI-guided theranostic platform for diagnosis, profiling, and therapeutic conditioning of biological systems through heterogeneous and variable electromagnetic fields, integrated with active and passive nanobots and an AI control layer based on Physics-Informed Neural Networks (PINNs). The invention defines a general-purpose wave–nano theranostic platform in which electromagnetic field configurations are dynamically controlled by AI models and used to guide, modulate, and interact with nanobots operating within biological systems. The same platform supports integrated diagnostic profiling and therapeutic action, enabling detection, monitoring, and active bio-physical intervention within a single adaptive architecture. The system is deployable in wearable, home, and hospital configurations. Current medical and bio-defence technologies typically separate diagnosis and therapy, rely on pathogen- or disease-specific protocols, and require predefined biological models. These approaches are poorly suited for complex, multifactorial pathologies, chronic conditions, and scenarios involving unknown, emergent, or non-characterized biological agents. The invention addresses this limitation by providing a closed-loop theranostic system capable of operating even in the absence of prior biological reference models. Unlike conventional systems, the proposed platform performs continuous diagnostic assessment and therapeutic modulation within the same framework. The use of PINN-based AI control enables adaptive coupling between physical constraints, measured bio-physical signals, and therapeutic parameters, allowing real-time tuning of both diagnostic and therapeutic actions. The integration of active and passive nanobots extends functionality beyond sensing, supporting localized therapeutic interaction, modulation, and response control. This results in a flexible, scalable, and pathology-agnostic theranostic platform, applicable across a wide range of medical conditions, including dual-use bio-defence and exobiology defence scenarios. The inventions are conceived as transferable technological building blocks, suitable for integration into existing product lines or for further proprietary development by the acquirer, and are explicitly not limited to pathogen inactivation alone. The IP is available for full assignment, exclusive or non-exclusive licensing, or option agreements. The technology has attracted institutional interest and has been included in preliminary discussions with the Italian Ministry of Defence, with a scheduled appointment in the context of the PNRM 2027 programme (submission deadline: December 2026). PCT extension decision deadline: January 17th. PCT filing may be carried out by the acquirer or licensee according to their strategic and territorial needs. Two Italian patent applications filed with UIBM (pending): – Application No. 102025000027763 date 27/10/2025 – Application No. 102025000000813 date 17/01/2025